Henry A Nasrallah
Affiliation: University of Cincinnati
- Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baselineHenry A Nasrallah
University of Cincinnati, Cincinnati, OH 45267 0559, USA
Schizophr Res 86:15-22. 2006....
- Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of SchizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
J Clin Psychiatry 70:4-46. 2009..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
- Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar maniaHenry A Nasrallah
University of Cincinnati College of Medicine, Cincinnati, OH, USA
Bipolar Disord 8:467-74. 2006..To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania...
- Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer
Department of Psychiatry, University of California at San Diego, USA
Biol Psychiatry 66:1013-22. 2009..Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment...
- A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267, USA
Neuropsychopharmacology 35:2072-82. 2010..All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia...
- Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and futureRajiv Tandon
University of Florida, Department of Psychiatry, FL, USA
Schizophr Res 122:1-23. 2010..We evaluate the potential contribution of pharmacogenomics and other biological markers in optimizing individual treatment and outcome in the future...
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Jonathan M Meyer
Department of Psychiatry, University of California, San Diego, USA
Schizophr Res 101:273-86. 2008..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
- Defining and measuring clinical effectiveness in the treatment of schizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
Psychiatr Serv 56:273-82. 2005..This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives...
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled studyHenry A Nasrallah
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45219, USA
J Psychiatr Res 47:670-7. 2013..All lurasidone doses were generally well tolerated...
- Neurologic comorbidities in schizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
J Clin Psychiatry 66:34-46. 2005..Such recognition may permit earlier identification and treatment of schizophrenia, thus potentially improving long-term outcome...
- Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidoneHenry A Nasrallah
Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center, 231 Albert Sabin Way, PO Box 670559, Cincinnati, OH 45267 0559, USA
J Clin Psychiatry 65:531-6. 2004..Results are discussed in the context of HRQoL in the general U.S. population...
- Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in ratsHenry A Nasrallah
Dept of Psychiatry, Univ of Cincinnati College of Medicine, Cincinnati, OH 45267 0521, USA
Brain Res 1354:23-9. 2010..This olfactory model can be employed in human research as a method to explore the neurogenesis effects of various pharmacologic treatments of neuropsychiatric disorders...
- Improving patient outcomes in schizophrenia: achieving remissionHenry A Nasrallah
University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
J Psychopharmacol 20:57-61. 2006..Remission may, therefore, be considered as a current goal of treatment today, not a distant future aim...
- Factors in antipsychotic drug selection: tolerability considerationsHenry A Nasrallah
University of Cincinnati Medical Center, Cincinnati, Ohio, USA
CNS Spectr 8:23-5. 2003..Regulatory agencies in some countries have already taken action in this regard...
- The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trialHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
J Clin Psychiatry 68:5-11. 2007..Except for clozapine, olanzapine clearly had the greatest metabolic side effect burden, and ziprasidone, the least. Perphenazine had the most motor side effects, although the rate was modest...
- Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophreniaElizabeth Gilday
Department of Psychiatry and Behavioral Neuroscience, University of Cincimati, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219, USA
Rev Recent Clin Trials 7:2-9. 2012..Current studies for clinical efficacy of paliperidone palmitate for both acute and maintenance treatment and adherence in adults with schizophrenia are discussed. Studies for safety and tolerability are also reviewed...
- Paliperidone: a new extended-release oral atypical antipsychoticHeather Dlugosz
University of Cincinnati, Department of Psychiatry, College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
Expert Opin Pharmacother 8:2307-13. 2007..At present, there are no published data from a comparative trial with paliperidone ER versus its parent compound or other second-generation antipsychotic agents...
- Schizophrenia, "just the facts" 4. Clinical features and conceptualizationRajiv Tandon
Department of Psychiatry, University of Florida College of Medicine, P O Box 100256, Gainesville, FL 32610, USA
Schizophr Res 110:1-23. 2009..Possible implications for DSM-V and ICD-11 definitions of schizophrenia are discussed...
- Neurological disorders in schizophreniaArman Danielyan
Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45244, USA
Psychiatr Clin North Am 32:719-57. 2009..In this article the most recent findings from multiple studies on neurological disorders in SZ are reviewed, and the authors make a strong argument for a neurological basis of the schizophrenic process...
- Metabolic findings from the CATIE trial and their relation to tolerabilityHenry A Nasrallah
University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
CNS Spectr 11:32-9. 2006..This article highlights the metabolic findings from the CATIE schizophrenia study, and explores the differences shown by atypical antipsychotics, with regard to metabolic side effects that increase cardiovascular risk...
- Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of careHenry A Nasrallah
Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center in Cincinnati, OH 45267 0559, USA
J Clin Psychopharmacol 24:S7-14. 2004..As clinicians refine practice patterns regarding the atypical antipsychotics, they may require additional knowledge and resources to fully incorporate risk/benefit considerations and optimize long-term psychiatric and medical outcomes...
- Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyondHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
J Clin Psychiatry 68:3-4. 2007
- Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouseMatcheri S Keshavan
Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Harvard Medical School, Boston, MA 02215, USA
Schizophr Res 127:3-13. 2011..The mouse may be the way to rescue the trapped elephant!..
- An overview of common medical comorbidities in patients with schizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
J Clin Psychiatry 66:3-4. 2005
- Focus on lower risk of tardive dyskinesia with atypical antipsychoticsHenry A Nasrallah
Departments of Psychiatry, Neurology, and Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Ann Clin Psychiatry 18:57-62. 2006..Identifying the risk factors for TD is important to minimize the risk of this potentially irreversible movement disorder in susceptible populations...
- Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective dataHenry A Nasrallah
Department of Psychiatry, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
Am J Geriatr Psychiatry 12:437-9. 2004..The authors examined the mortality rate in geriatric patients receiving either haloperidol or atypical antipsychotics...
- Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposureMikhil Bamne
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
Schizophr Bull 38:1149-54. 2012..3-22.1, the human leukocyte antigen (HLA) region, as common risk factors for schizophrenia (SZ). Other studies implicate viral and protozoan exposure. Our study tests chromosome 6p SNPs for effects on SZ risk with and without exposure...
- Efficacy, safety, and tolerability of quetiapine in patients with schizophreniaHenry A Nasrallah
Department of Psychiatry, University of Mississippi Medical Center, Jackson, Miss, USA
J Clin Psychiatry 63:12-20. 2002..This article will review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in the treatment of patients with schizophrenia...
- Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literatureHenry A Nasrallah
Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45267 0559, USA
J Affect Disord 95:69-78. 2006..Controlled and direct comparative studies, both short and long term, are needed to further clarify the differences between VPA and CBZ...
- The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophreniaHenry A Nasrallah
University of Cincinnati College of Medicine, Cincinnati, OH, USA
CNS Spectr 13:5-6. 2008
- The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatristsJohn W Newcomer
Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
J Clin Psychopharmacol 24:S1-6. 2004..The impact of additional data and educational efforts in this area, such as a recently published consensus statement from the American Diabetes Association and other organizations, remains to be assessed...
- Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Jonathan M Meyer
Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
Schizophr Res 103:104-9. 2008..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
- Risperidone in the treatment of delirium: results from a prospective open-label trialDinesh Mittal
Department of Veterans Affairs Medical Center, Jackson, Mississippi 39216, USA
J Clin Psychiatry 65:662-7. 2004..Effective treatment is necessary to reverse delirium and prevent potentially serious consequences...
- Academic highlights: guidelines for the use of long-acting injectable atypical antipsychoticsSamuel J Keith
J Clin Psychiatry 65:120-31. 2004
- Schizophrenia and aging: no more dearth of data?Dilip V Jeste
Am J Geriatr Psychiatry 11:584-7. 2003
- Treatment of bipolar disorderHans Jurgen Moller
Psychiatric Department of University Munich, Munich, Germany
J Clin Psychiatry 64:9-17; discussion 28. 2003..This article provides an overview of current management strategies for patients with bipolar disorder and describes how these approaches can be incorporated into clinical practice...
- Pharmacoeconomic implications of adverse effects during antipsychotic drug therapyHenry A Nasrallah
University of Mississippi Medical Center, Veterans Affairs Medical Center, Jackson, MS, USA
Am J Health Syst Pharm 59:S16-21. 2002..A comprehensive evaluation of risk factors, outcomes, and costs should be include in economic evaluations of antipsychotic drugs so that realistic strategies for reducing costs and improving health can be identified...
- The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapyFrank Gianfrancesco
HECON Associates, Inc, Montgomery Village, MD, USA
Ann Clin Psychiatry 18:9-17. 2006..Retrospective large patient database studies have reported conflicting findings regarding diabetes risks associated with antipsychotics. This study compared two study designs to assess antipsychotic-related diabetes risk...
- Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI studyMichael A Cerullo
Schizophr Res 97:294-6. 2007
- A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsDonald C Goff
Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
Schizophr Res 80:45-53. 2005..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics...
- Pain insensitivity in schizophrenia: trait or state marker?Manpreet K Singh
University of Cincinnati College of Medicine and Cincinnati Children s Hospital Medical Center, 45267, USA
J Psychiatr Pract 12:90-102. 2006..We therefore reviewed the literature for findings concerning whether pain insensitivity in schizophrenia represents a state or a trait marker...
- Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIIJoseph P McEvoy
Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
Schizophr Res 80:19-32. 2005..One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia...
- The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer
VA San Diego Healthcare System, USA
Schizophr Res 80:9-18. 2005....
- Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent dosesRajiv Tandon
Arch Gen Psychiatry 63:935-7; author reply 937-9. 2006
- Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan databaseFrank D Gianfrancesco
HECON Associates, Montgomery Village, MD 20886, USA
J Clin Psychiatry 63:920-30. 2002..Case series suggest that some antipsychotics may induce or exacerbate type 2 diabetes. This study measured the association of antipsychotic treatments with diabetes at a population level...
- Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapyHenry A Nasrallah
J Psychopharmacol 20:3-5. 2006
- Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderRobert Lasser
Janssen Pharmaceutical Products, LP, Titusville, NJ, USA
J Affect Disord 83:263-75. 2004..Data from a large study (n=725), which included schizoaffective patients to assess the effect of long-acting risperidone, are presented...
- Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorderTerence A Ketter
Stanford University School of Medicine, Stanford, CA 94305, USA
Psychopharmacol Bull 39:120-46. 2006..Further investigation of combinations of agents such as mood stabilizers and atypical antipsychotics may yield valuable insights into the potential of combination therapies to enhance clinical outcomes in patients with bipolar disorder...
- Strategies for maximizing clinical effectiveness in the treatment of schizophreniaRajiv Tandon
Florida Department of Children and Families, Tallahassee, FL 32399, USA
J Psychiatr Pract 12:348-63. 2006..Finally, the effectiveness of providing optimal individualized treatment/rehabilitation is best gauged by measuring progress on multiple effectiveness domains. Approaches for efficient and reliable assessment are discussed...
- Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studiesKrishnan Ramaswamy
Janssen Pharmaceutica Products, LP, Titusville, New Jersey, USA
Ann Clin Psychiatry 18:183-94. 2006..Some atypical antipsychotics have been linked to hyperglycemia, diabetes mellitus, and diabetic ketoacidosis. We reviewed evidence comparing excess risk and relative risk of type-2 diabetes associated with atypical antipsychotics...
- Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendationsJohn W Newcomer
Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
CNS Spectr 13:13-4. 2008
- Improving the pedagogy associated with the teaching of psychopharmacologyIra D Glick
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
Acad Psychiatry 31:211-7. 2007..The focus was on whether "improving the teaching-learning process" in psychiatric residency programs could improve clinical practice...
- Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in ratsAlvin V Terry
Department of Pharmacology and Toxicology, CB 3618, Medical College of Georgia, 1120 Fifteenth St, Augusta, GA 30912 2450, USA
J Pharmacol Exp Ther 318:709-24. 2006..e., important neurobiological substrates of memory), and cognitive function...
- Celebrating twenty years of schizophrenia researchLynn E DeLisi
Schizophr Res 100:1-3. 2008
- Schizophrenia, "Just the Facts": what we know in 2008 part 1: overviewRajiv Tandon
University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
Schizophr Res 100:4-19. 2008..We intend to follow this paper with the submission to the journal of a series of topic-specific articles, critically reviewing the evidence...
- Antipsychotic-induced type 2 diabetes: evidence from a large health plan databaseFrank Gianfrancesco
HECON Associates, 9833 Whetstone Drive, Montgomery Village, MD 20886, USA
J Clin Psychopharmacol 23:328-35. 2003..This study supports earlier findings on risperidone versus olanzapine and builds evidence on quetiapine. Additional studies are needed to evaluate the association of antipsychotic treatment with type 2 diabetes...
- Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiologyRajiv Tandon
University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
Schizophr Res 102:1-18. 2008..The ability to question some of our basic assumptions about the etiology and nature of schizophrenia and greater rigor in its study appear critical to improving our understanding about its causation...